Antibacterial medicine sales in Canada are forecasted to decline steadily from 2024 to 2028, with per capita values decreasing each year. From 7.4 USD per capita in 2024, the values are expected to fall by an average CAGR of 8.9% annually over five years to reach 5.1 USD per capita by 2028. The year-on-year percentage declines highlight a downward slope indicating reduced usage or shifting focus in antibiotics consumption.
Looking ahead, an increased emphasis on antimicrobial resistance and shifts toward alternative treatments could further impact sales. Monitoring changes in healthcare policies and innovation in antibacterial treatments will be critical for understanding future trends.
